Megan Silas, MD
Ophthalmology · Hammond, INNPI 1821450578
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,172 of the $5,472 with a category attached, or 76.2%. 24 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 26.7% of the total. Reporting peaked in 2024 at $1,952 and has fallen 69.9% since, to $588 in 2025.
Across 81 payments — averaging $67.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$1K
- Alcon$780
- AbbVie$596
- Amgen$364
- Regeneron Healthcare Solutions, Inc.$356
- Biotissue Holdings Inc.$323
- plus $2K from 18 others
What the payments were for
- Consulting fees$1,30024%
- Food & beverage$4,17276%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 7 | $1,458 |
| Alcon | 11 | $780 |
| AbbVie(2 entities) | 7 | $596 |
| Amgen(2 entities) | 8 | $364 |
| Regeneron Healthcare Solutions, Inc. | 3 | $356 |
| Biotissue Holdings Inc. | 9 | $323 |
| Novartis | 5 | $316 |
| Glaukos Corporation | 1 | $203 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $179 |
| Bausch & Lomb Americas Inc. | 2 | $158 |
| NEW World Medical,inc. | 1 | $127 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $109 |
| Dompe US, Inc. | 3 | $75 |
| Harrow Eye, LLC | 3 | $70 |
| Sun Pharmaceutical Industries Inc. | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Aerie Pharmaceuticals, Inc. | 2 | $45 |
| Sight Sciences, Inc. | 2 | $44 |
| Eyevance Pharmaceuticals LLC | 2 | $42 |
| Thea Pharma Inc. | 2 | $34 |
| Oyster Point Pharma, Inc. | 1 | $28 |
| Biogen | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$1,300
- EYLEA$356
- Clareon$296
- OZURDEX$268
- BEOVU$248
- TEPEZZA$231
- Tecnis IOL$218
- iStent Infinite$203
- iDoseTR$203
- XEN GLAUCOMA TREATMENT SYSTEM$150
- AcrySof$142
- MIEBO$139
- XIIDRA$139
- Kahook Dual Blade$127
- Clearpath$127
- Ahmed Glaucoma Valve$127
- Streamline$127
- VUITY$125
- ENVISTA$123
- Prokera$122
How this compares
$5,472 in reported general payments places this provider in the 80th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 11 | $20,255 |
| RestasisCyclosporine | 11 | $6,932 |
| LumiganBimatoprost | 11 | $4,834 |
| Prednisolone Acetate | 66 | $2,332 |
| Latanoprost | 127 | $2,212 |
| ErythromycinErythromycin Base | 159 | $1,665 |
| Ketorolac Tromethamine | 51 | $1,613 |
| MoxifloxacinMoxifloxacin Hcl | 52 | $1,011 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $832 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 40 | $653 |
| Timolol Maleate | 45 | $376 |
| Dorzolamide Hcl | 28 | $264 |
| Brimonidine Tartrate | 14 | $245 |
| Alprazolam | 11 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,458 | $20,25511 claims |
| AbbVieRestasis, Lumigan | $596 | $11,76622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Hammond
- Blake WilliamsHammond$6K
- Ann WilliamsHammond$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.